Citizens JMP raised the firm’s price target on Rezolute (RZLT) to $17 from $9 and keeps an Outperform rating on the shares. Rezolute remains on track to report top-line data in December from the Phase 3 sunRIZE study evaluating ersodetug in congenital hyperinsulinism, the analyst tells investors in a research note. Citizens remains confident in the potential for positive results driven by compelling efficacy and safety/tolerability demonstrated in the Phase 2b study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Promising Prospects for Rezolute: Buy Rating Backed by Innovative Lead Candidate and Favorable Market Conditions
- 3 ‘Strong Buy’ Small-Cap Stocks Set to Surge, According to Analysts
- 3 Must-See Stocks with Strong-Buy Ratings and a Perfect 10 Score
- Rezolute price target raised to $20 from $15 at Maxim
- Rezolute’s Promising Progress and Financial Strength Justify Buy Rating